Compare BridgeBio Pharma Inc (BBIO) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Trip.com Group Ltd — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Trip.com Group Ltd trades at $42.65 (market cap $26.95B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TCOM | |
|---|---|---|
Market Cap | $16.46B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $78.96 |
52-Week Low | $44.81 | $39.84 |
Enterprise Value | $18.02B | $19.65B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TCOM trades at $42.36, down 1.03% on the day, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a P/E of 6.36, net income margin of 48.65%, and robust cash flow from operations of $19.63 billion in 2024. However, Q1 2026 earnings missed estimates, and Q2 revenue guidance of 3%-8% growth disappointed investors, contributing to recent price weakness.
The outlook is mixed; strong profitability and low valuation offer upside toward the $56.72 consensus price target, but near-term headwinds include regulatory scrutiny and muted guidance. Risks involve antitrust investigations and domestic travel dependency, yet institutional sentiment remains positive with 67% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
